inotuzumab ozogamicin
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
in-oh-tooz-ue-mab oh-zoe-ga-mye-sin
To hear audio pronunciation of this topic, purchase a subscription or log in.
Trade Name(s)
- Besponsa
Ther. Class.
Pharm. Class.
drug-antibody conjugates
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Inotuzumab Ozogamicin." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110696/all/inotuzumab_ozogamicin.
Vallerand AHA, Sanoski CAC, Quiring CC. Inotuzumab ozogamicin. Davis's Drug Guide. F.A. Davis Company; 2024. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110696/all/inotuzumab_ozogamicin. Accessed December 1, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Inotuzumab ozogamicin. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110696/all/inotuzumab_ozogamicin
Vallerand AHA, Sanoski CAC, Quiring CC. Inotuzumab Ozogamicin [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 December 01]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110696/all/inotuzumab_ozogamicin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - inotuzumab ozogamicin
ID - 110696
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/110696/all/inotuzumab_ozogamicin
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -